Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma

References

Page 1

	Year	Citations
Global cancer statistics Ahmedin Jemal, Freddie Bray CA A Cancer Journal for Clinicians	2011	55K
Sorafenib in Advanced Hepatocellular Carcinoma Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, New England Journal of Medicine	2008	12.8K
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen, The Lancet Oncology HepatologyMedicineCancer ManagementPhase IiiClinical Trials	2008	5.8K
Sorafenib in Advanced Hepatocellular Carcinoma 재연 정 HepatologyMedicinePathologyLiver CancerOncology	2008	5.6K
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis Scott M. Wilhelm, Christopher Carter, LiYa Tang, Cancer Research Mutant BrafRaf/mek/erk PathwayMedicineTumor GrowthMutant Kras	2004	4K
The National Comprehensive Cancer Network (NCCN). Elizabeth H. Wood Europe PMC (PubMed Central) Pdf GuidelinesCancer EpidemiologyMedicineCancer ManagementClinical Specialties	2004	2.9K
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Poulikos I. Poulikakos, Chao Zhang, Gideon Bollag, Nature Signal TransductionSignaling PathwayCell RegulationMedicineReceptor Tyrosine Kinase	2010	1.8K
Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy Bret B. Friday, Alex A. Adjei Clinical Cancer Research	2008	379
Mutations of the <i>BRAF</i> gene in cholangiocarcinoma but not in hepatocellular carcinoma Andrea Tannapfel Gut	2003	341
Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma Yoshiki Ito, Yutaka Sasaki, Masayoshi Horimoto, Hepatology Signal TransductionHepatologyTumor MicroenvironmentHuman Hepatocellular CarcinomaHuman Hcc	1998	337

Page 1